Omadacycline
- TRADE NAME: Nuzyra (Paratek Pharms Inc)
- INDICATIONS: indicated for the treatment of adult patients with the following infections caused by susceptible microorganisms
- CLASS: Antibiotic, Antibiotic; tetracycline
- HALF-LIFE: ~16 hours
FDA APPROVAL DATE: 10/02/2018
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:None known
PREGNANCY CATEGORY: N/A
insufficient data to inform drug associated risk
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OCULAR.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric